These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9129086)
1. Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration. Bürgisser P; Spertini F; Weyrich-Suter C; Pagani JL; Meylan PR J Infect Dis; 1997 May; 175(5):1202-5. PubMed ID: 9129086 [TBL] [Abstract][Full Text] [Related]
2. HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study. Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Delbeke E; J Acquir Immune Defic Syndr; 2001 Oct; 28(2):154-7. PubMed ID: 11588509 [TBL] [Abstract][Full Text] [Related]
3. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215 [TBL] [Abstract][Full Text] [Related]
4. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838 [TBL] [Abstract][Full Text] [Related]
5. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849 [TBL] [Abstract][Full Text] [Related]
6. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment. Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742 [TBL] [Abstract][Full Text] [Related]
7. Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. Andreoni M; Sarmati L; Ercoli L; Nicastri E; Giannini G; Galluzzo C; Pirillo MF; Vella S AIDS Res Hum Retroviruses; 1997 May; 13(7):555-61. PubMed ID: 9135873 [TBL] [Abstract][Full Text] [Related]
8. Viral load and immunophenotype of cells obtained from lymph nodes by fine needle aspiration as compared with peripheral blood cells in HIV-infected patients. Meylan PR; Bürgisser P; Weyrich-Suter C; Spertini F J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Sep; 13(1):39-47. PubMed ID: 8797685 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine. Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672 [TBL] [Abstract][Full Text] [Related]
11. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503 [TBL] [Abstract][Full Text] [Related]
13. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127 [TBL] [Abstract][Full Text] [Related]
14. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine. Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824 [TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. Lafeuillade A; Poggi C; Profizi N; Tamalet C; Costes O J Infect Dis; 1996 Aug; 174(2):404-7. PubMed ID: 8699075 [TBL] [Abstract][Full Text] [Related]
16. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446 [TBL] [Abstract][Full Text] [Related]
17. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378 [TBL] [Abstract][Full Text] [Related]
18. Lymph node human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir. Schapiro JM; Winters MA; Vierra M; Crawford S; Merigan TC J Infect Dis; 1998 Feb; 177(2):477-80. PubMed ID: 9466542 [TBL] [Abstract][Full Text] [Related]
19. Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Swiss HIV Cohort Study. Bart PA; Meuwly JY; Corpataux JM; Yerly S; Rizzardi P; Fleury S; Munoz M; Knabenhans C; Welbon C; Pantaleo G; Meylan PR AIDS; 1999 Aug; 13(12):1503-9. PubMed ID: 10465074 [TBL] [Abstract][Full Text] [Related]
20. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. Lafeuillade A; Poggi C; Tamalet C; Profizi N; Tourres C; Costes O J Infect Dis; 1997 May; 175(5):1051-5. PubMed ID: 9129065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]